Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)

Trial Profile

Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tinzaparin sodium (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms PREDICARE
  • Sponsors LEO Pharma
  • Most Recent Events

    • 06 Nov 2019 Results describing prescription and use of the anticoagulant treatment beyond 6 months and up to 12 months and to measure clinical outcomes in Cancer-associated Thrombosis patients initially treated with tinzaparin in 2 trials (NCT02898051, NCT03099031) released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
    • 07 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top